Grant: Operating Grant
Sunnybrook Research Institute (Toronto, Ontario)
$380,709.00
Metabolic Regulation of Toll-like Receptor Agonist Therapy in Leukemia
EF 2008-09
Résumé
Chemotherapy does not cure most cancers. However, the results with chemotherapy may be improved with treatments that increase the ability of the immune system to kill cancer cells (or immunotherapy). We have found that a new agent (called S28690), which activates a receptor on immune cells, called Toll-like receptor 7 (or TLR7), makes tumor cells more susceptible to both chemotherapy in the test tube but is not as effective in patients. The proposed research will determine how to make S28690 more effective in patients with Chronic Lymphocytic Leukemia, which is a tumor of the blood system. If these studies are successful,a new treatment for leukemia, and possibly other cancers, will become available.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
170526
Name
Spaner David E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
Metabolic Regulation of Toll-like Receptor Agonist Therapy in Leukemia
Programtype2
Operating Grants
Orgnameinp2
Sunnybrook Research Institute (Toronto, Ontario)
Cihramount2
$380,709
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Apoptosis; Cancer; Cytokines; Flow Cytometry; Glucose; Mitochondria
Abstract
Chemotherapy does not cure most cancers. However, the results with chemotherapy may be improved with treatments that increase the ability of the immune system to kill cancer cells (or immunotherapy). We have found that a new agent (called S28690), which activates a receptor on immune cells, called Toll-like receptor 7 (or TLR7), makes tumor cells more susceptible to both chemotherapy in the test tube but is not as effective in patients. The proposed research will determine how to make S28690 more effective in patients with Chronic Lymphocytic Leukemia, which is a tumor of the blood system. If these studies are successful,a new treatment for leukemia, and possibly other cancers, will become available.
Competitiondate
200809
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Spaner, David E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $380,709~ $0~
